Xenon Pharmaceuticals (NASDAQ:XENE) Given Outperform Rating at William Blair

William Blair reissued their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Other analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $37.02 on Friday. The stock’s fifty day moving average is $39.27 and its two-hundred day moving average is $40.33. The firm has a market capitalization of $2.82 billion, a P/E ratio of -13.13 and a beta of 1.20. Xenon Pharmaceuticals has a fifty-two week low of $33.27 and a fifty-two week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. As a group, sell-side analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,492 shares of company stock worth $2,334,969 over the last ninety days. Company insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $63,000. Quarry LP acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth about $78,000. Avior Wealth Management LLC purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $101,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.